Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Akebia Therapeutics (AKBA) FCF Margin (2017 - 2025)

Historic FCF Margin for Akebia Therapeutics (AKBA) over the last 9 years, with Q3 2025 value amounting to 47.69%.

  • Akebia Therapeutics' FCF Margin rose 655900.0% to 47.69% in Q3 2025 from the same period last year, while for Sep 2025 it was 14.3%, marking a year-over-year decrease of 2470500.0%. This contributed to the annual value of 25.4% for FY2024, which is 2084400.0% up from last year.
  • As of Q3 2025, Akebia Therapeutics' FCF Margin stood at 47.69%, which was up 655900.0% from 35.57% recorded in Q2 2025.
  • Over the past 5 years, Akebia Therapeutics' FCF Margin peaked at 69.39% during Q3 2022, and registered a low of 135.37% during Q1 2021.
  • Over the past 5 years, Akebia Therapeutics' median FCF Margin value was 23.73% (recorded in 2025), while the average stood at 36.19%.
  • Per our database at Business Quant, Akebia Therapeutics' FCF Margin tumbled by -1605700bps in 2021 and then skyrocketed by 1848100bps in 2022.
  • Over the past 5 years, Akebia Therapeutics' FCF Margin (Quarter) stood at 108.9% in 2021, then increased by 10bps to 98.02% in 2022, then soared by 102bps to 1.8% in 2023, then plummeted by -635bps to 9.61% in 2024, then skyrocketed by 596bps to 47.69% in 2025.
  • Its last three reported values are 47.69% in Q3 2025, 35.57% for Q2 2025, and 23.73% during Q1 2025.